Skip to main content

COVID-19: dealing with a potential risk factor for chronic neurological disorders


SARS-CoV2 infection is responsible for a complex clinical syndrome, named Coronavirus Disease 2019 (COVID-19), whose main consequences are severe pneumonia and acute respiratory distress syndrome. Occurrence of acute and subacute neurological manifestations (encephalitis, stroke, headache, seizures, Guillain–Barrè syndrome) is increasingly reported in patients with COVID-19. Moreover, SARS-CoV2 immunopathology and tissue colonization in the gut and the central nervous system, and the systemic inflammatory response during COVID-19 may potentially trigger chronic autoimmune and neurodegenerative disorders. Specifically, Parkinson’s disease, multiple sclerosis and narcolepsy present several pathogenic mechanisms that can be hypothetically initiated by SARS-CoV2 infection in susceptible individuals. In this short narrative review, we summarize the clinical evidence supporting the rationale for investigating SARS-CoV2 infection as risk factor for these neurological disorders, and suggest the opportunity to perform in the future SARS-CoV2 serology when diagnosing these disorders.


In December 2019, a novel coronavirus, named severe acute respiratory syndrome-coronavirus 2 (SARS-CoV2), emerged from China and spread worldwide as pandemic. SARS-CoV2 infection is responsible for a heterogeneous clinical syndrome, leading to severe pneumonia and acute respiratory distress syndrome (ARDS), titled coronavirus disease 2019 (COVID-19). The occurrence of neurological manifestations, including encephalitis, stroke, headache, seizures, Guillain–Barrè syndrome, is increasingly reported in patients with COVID-19 [1,2,3,4]. Although these neurological manifestations of COVID-19 suggest a possibly acute or subacute neuropathogenicity of the virus, the risk of long-term neurological sequelae in patients affected by SARS-CoV2 is not understood and currently debated [5, 6].

Available data on COVID-19 currently disclosed that SARS-CoV2 can induce, directly or indirectly, a number of clinical manifestations and immune–inflammatory events, including viral–host interactions, that might shape pathogenic mechanisms underlying common chronic neuroinflammatory and neurodegenerative disorders [2, 5, 6].

In this review, we will specifically discuss the biological events possibly initiated by SARS-CoV2 infection potentially overlapping with etiological mechanisms featuring Parkinson’s disease (PD), multiple sclerosis (MS), or narcolepsy. Building on these evidences, we will highlight the need to monitor patients affected by COVID-19 who can develop PD, MS, or narcolepsy as long-term neurological consequences of the infection.

Parkinson’s disease

PD is the second most common neurodegenerative disorder, characterized by progressive motor and non-motor disturbances, due to the loss of dopaminergic cells in the substantia nigra pars compacta (SNpc) and the accumulation of α-synuclein (α-syn)-positive Lewy bodies [7,8,9]. The relationship between viral infections and PD has its roots in the early twentieth century, when a number of post-encephalitic parkinsonism were observed following an influenza outbreak. Aside from this historical event, infectious diseases, including viral infections, have been demonstrated increasing the risk for PD by 20% [10]. The mechanisms underlying this association may imply a direct neuronal injury due to the central nervous system (CNS) invasion by viruses and subsequent loss of dopaminergic cells into the SNpc. Indeed, it has been recently demonstrated in Rag knockout mice that H1N1 Influenza-A virus infection inhibits protein degradation at autophagosome–lysosome system level and precipitates α-syn accumulation [11]. Further experimental evidence showed that Influenza-A virus disrupts mitochondrial activity and increase oxidative stress [12, 13], whereas hepatitis C virus impairs dopaminergic transmission and affects the blood–brain barrier (BBB) integrity [10]. Therefore, viral infections may intervene in cellular pathways critical for PD pathogenesis, probably contributing to the initiation of the disease [8, 9, 14,15,16,17].

Although the CNS colonization by SARS-CoV2 has been proven, the consequences on neurons at a molecular level have been only hypothesized [5, 6]. However, it is interesting to note that the virus may affect brain areas particularly involved in early phases of PD neurodegeneration. Many patients with COVID-19 indeed complained of anosmia and ageusia [18], which are two classical prodromal features of PD [19]. Actually, SARS-CoV2 might invade the brain through the olfactory tracts and spread towards the piriform and infralimbic cortex, the basal ganglia and the brainstem [18]. Neuropathological evidence suggests that, in PD, Lewy body accumulation is primarily localized in the olfactory pathway, and then propagates to other brain structures following olfactory system connections causing neuronal degeneration [19, 20]. This potential overlap between the SARS-CoV2 propagation and the spreading of PD neuropathology is particularly alarming if we consider that some patients with COVID-19 do not recover (or partially recover) smell sense [18], thus, indicating a possible neuronal injury that in turn might trigger the synucleinopathy cascade [21]. Aside from the direct invasion of CNS, SARS-CoV2 might increase the risk for PD because of the induction of a systemic inflammatory state [22]. Cytokine production is fundamental in the immunological response to viruses. However, an excessive and dysregulated release of interferons (IFNs), interleukin (IL)-1β, IL-6, tumour necrosis factor (TNF) and chemokines (C–C motif chemokine ligand, CCL-2, CCL-3, and CCL-5), shaping the so-called cytokine storm, can be deleterious, causing an immune-mediated attack to human organs [23]. COVID-19 patients present a systemic inflammatory state, as demonstrated by the significant increase of C-reactive protein (CRP), IL-6, IL-8, IL-10, IL-2R, and ferritin blood levels [24]. Similar profile of peripheral inflammation is notably observed in PD patients, who exhibit higher blood levels of CRP and proinflammatory cytokines (IL-6, TNF, IL-1β and IL-2) [25, 26], directly correlated with clinical severity [27]. The inflammatory activation due to COVID-19 may thus disrupt the systemic homeostasis at the CNS level, where it could trigger and feed initial steps of synucleinopathy, favouring PD onset, as compelling experimental evidence suggests [22, 28].

COVID-19 is also responsible for gastrointestinal symptoms [29], and SARS-CoV2 RNA has been tracked in the faeces of infected patients indicating an intestinal localization of the virus. A recent study demonstrated that enterocytes represent major target cells of SARS-CoV2 reacting to the infection with a strong inflammatory response [30]. These findings might further highlight the role of COVID-19 as a potential risk factor for PD. In fact, an experimental intestinal infection was able to turn PINK1 asymptomatic mouse model into a fully penetrant model, with levodopa-responsive motor symptoms, probably trough an immune-mediated multisystem mechanism [31]. Moreover, SARS-CoV2 intestinal infection may alter gut microbiota and gut physiology overall [32], influencing all factors providing the “peripheral” contribute to PD pathogenesis and progression [33].

Finally, it should be also considered psychiatric comorbidity of COVID-19. Actually, patients can develop depression, anxiety and fatigue, which may have both psychological and organic causes [34]. Regardless of the cause, mood disorders are associated with neuroinflammation and often exert detrimental effects on CNS, contributing to neurodegeneration [35]. Hence, COVID-19 definitely represents a stressful event that may have a role in triggering PD [36].

Multiple sclerosis

MS is a chronic immune-mediated disease of the CNS whose pathological hallmark is focal demyelination associated with various degrees of neurodegeneration [37]. Complex immunological dysfunction—involving peripheral T and B lymphocytes and resident CNS immune cells—represents the immunological substrate for MS development and progression [38]. The intermittent aberrant activation of self-reacting immune cell subsets results in their transmigration across the BBB into the CNS, where they induce demyelinating and, ultimately, neuronal damage manifesting as clinical relapse and disability accumulation. The aetiology of the disease, as well as its periodic relapses, is not established yet, but environmental triggers acting on susceptible individuals are implicated. For over a century, since Pierre Marie initial intuition in 1884, MS was believed to be caused by infectious agents and many viruses, including coronavirus, have been proposed as potential candidates [39]. Viral infection contributes to demyelination through several mechanisms such as molecular mimicry, bystander inflammatory damage or direct oligodendrocyte infection [39]. MS onset may occur long after acute infection as consistently demonstrated for by Epstein–Barr virus (EBV) [40]. Infectious mononucleosis by EBV supervening during the early adulthood, in fact, is an established risk factor for further MS development [41,42,43,44,45]; moreover, compelling evidence shows that almost all subjects with MS have positive serology for EBV. The “prime/challenging” theory has been proposed to explain the delay between early infection and MS onset; according to this assumption, the initial infection, such as by EBV, would prime autoreactive cells in susceptible individuals via molecular mimicry and bystander activation, setting up a fertile-field. Further infection by other microorganism, or even reactivation of EBV under favouring circumstances, will activate the preexisting autoreactive cells leading to inflammatory demyelination [40, 46]. Studies in MS patients infected by SARS-CoV2 are ongoing aiming at identifying the effects of iatrogenic immune modulation/suppression on the severity of infection [47, 48]. Nevertheless, the effect of the virus on MS-related inflammatory activity has not been investigated yet, but few cases of acute inflammatory demyelinating disorder have been already described. It would not be surprising that SARS-CoV2 might act as “priming” or “challenging” infectious agent in “primed” individuals. Moreover, in individuals with MS, autoreactive T cells able to recognize both viral and myelin antigens have been found [49]. Additionally, SARS-CoV2 infection is associated with peripheral lymphopenia in more than 80% of patients with COVID-19. Lymphopenia is sustained by a predominant decrease of CD3 + , CD8 + , and CD4 + T cell counts, while B cells and NK are only mildly affected [50]. Patients infected by SARS-CoV during the 2002–04 outbreak recovered normal T lymphocytes count in about 2 months in the majority of case, and more rarely the recovery took more than 12 months [51]. Sequestration in the lung, intestine and other tissues, and senescence and exhaustion of the anti-viral CD8 response [50, 52], explain this selective immunodepletion. We can speculate that defective anti-viral CD8 immunological response may reduce immunosurveillance on other latent pathogens potentially able to trigger MS or other post-infectious demyelinating disorders, such as Guillain–Barrè syndrome or its variants [53]. Co-infection with EBV, in fact, has been observed in patients affected by COVID-19, mainly in those with lower CD4/CD8 ratio [54]. Nevertheless, unbalance of peripheral lymphocyte subsets induced by COVID-19, and in particular B cell overshooting, may hypothetically represent an additional risk for MS relapses in patients with pre-existing diagnosis, as observed in similar immunological framework [55]. The “cytokine storm” in response to the SARS-CoV2 infection may promote a switch toward a pro-inflammatory status of T cell subsets, such as Th17, which are implicated in MS pathogenesis [56]

COVID-19 may indeed trigger MS or its clinical manifestation also through other mechanisms. In MS, intestinal dysbiosis and changes in intestinal permeability are increasingly recognized as modulators of neuroinflammatory mechanisms through the so-called gut–brain axis [57]. Therefore, the alteration of the intestinal barrier and microbiota induced by SARS-CoV2 may enhance autoreactive response (as previously mentioned).

Finally, it is worth noting that SARS-CoV2 is able to directly infect the CNS via olfactory pathway or hematogenous route using the angiotensin-converting enzyme receptor type 2 (ACE2) expressed in the CNS and in the vascular endothelium [6].

Coronaviruses, such as mouse hepatitis virus, may invade neurons and oligodendrocytes, establish a persistent infection of astrocytes and locally activate and immortalize microglial cells causing brain and spinal demyelination featuring MS, as observed in animal models and humans [58,59,60,61]. Moreover, strains of human coronavirus have been found in brain autoptic specimens of patients with MS [62]; additionally, MS patients show higher intrathecal antibody synthesis against coronaviruses than matched controls [45].

Building on these evidences, MS may result from previous SARS-CoV2 infection due several mechanisms: (1) a “challenging” effect of the virus in susceptible subjects previously exposed to priming pathogens; (2) unbalance of peripheral lymphocyte subsets and massive cytokine release producing a pro-inflammatory environment and triggering autoimmune reactions; (3) induction of post-infectious demyelinating events associated with direct CNS invasion and microglial reaction.


Narcolepsy is a rare sleep disorder featured by excessive daytime sleepiness (EDS) and REM sleep-associated symptoms, such as cataplexy (loss of muscle tone triggered by strong emotions), hypnagogic/hypnopompic hallucinations, and sleep paralysis. The prevalence of narcolepsy in 2016 was of 44.3 per 100,000 persons [63]. The main increase in narcolepsy diagnosis was in particular evident following Influenza-A H1N1 pandemic in 2009, and was evident in both patients affected by Influenza-A H1N1 and in patients vaccinated against this virus with Pandemrix (an adjuvanted vaccine) [64]. International classification of Sleep Disorders—3rd Edition classifies narcolepsy into two types, namely narcolepsy types 1 and 2 (NT1/2) [65]. The main clinical difference between these two forms of narcolepsy is the occurrence of cataplexy, which is the result of orexin (OX) neuron degeneration [65]. The OX system degeneration results in the not detectable levels of OX in the cerebrospinal fluid (CSF), consisting of the main diagnostic feature of NT1 [66]. Conversely, in NT2, the partial degeneration of OX neurons corresponds to normal CSF OX levels [67].

The main pathogenic causes of narcolepsy have been exclusively supposed with different levels of evidence since OX neuron degeneration remains a not-well-explained phenomenon. Several lines of evidence suggest that narcolepsy arises from the interaction of genetic, environmental and triggering factors, which leads to an immune-mediated selective loss or dysfunction of OX neurons in the brain lateral hypothalamus. Briefly, as summarized by Bassetti and coauthors [68], genetic factors (especially HLA-DQB1*06:02 positivity) are a strong predisposition to narcolepsy. Ensuing this genetic susceptibility, environmental exposures to bacterial and viral infections may alter or trigger the immune system reaction that in turn may attack the OX neurons. Several researches have been performed to understand the cascade of events leading to OX system and involving the different subsets of immune cells (B cells, T CD4 + and T CD8 + cells) [69, 70]. Not significant results have been achieved regarding the detection of specific autoantibodies produced by B cells [71]; conversely, T cells seem to have direct and indirect effects on OX neurons. In particular, in 2018, autoreactive CD4 + and CD8 + T cells targeting antigens expressed by OX neurons have been documented in patients with NT1 or NT2 [72]. This research highlighted the role of T cells in the pathogenesis of narcolepsy; however, the lack of proliferation of T cell clones in response to H1N1 influenza vaccine does not permit to achieve a definite conclusion [72]. Therefore, although widely supposed the role of T cells in the pathogenesis of narcolepsy, the chain of events producing OX neuron degeneration has not been completely identified. Finally, the increased levels of specific cytokines (TNF and IL-6 among others) further support the evidence of an inflammatory and immune response in patients with narcolepsy since the very early phases of the disease [73]. The reduction of CSF ß-amyloid42 levels in patients with narcolepsy near to disease onset has been also associated with the brain inflammatory response [74,75,76]. Moreover, other proofs of the activation of the immune system have been documented in patients with NT1, also with long-lasting disease [77].

The SARS-CoV2 viral outbreak may also present a unique opportunity to better understand the association between immune system activation and the development of autoimmune conditions such as narcolepsy [78]. Considering the non-haematological routes of infection, SARS-CoV2 can migrate from the olfactory bulb to hypothalamus and affect the OX neurons [78]. In keeping with this hypothetical model of CNS damage, the olfactory bulb may represent a link between environmental agents (such as SARS-CoV2) and narcolepsy, in patients with a genetic predisposition [79]. The olfactory bulb, in fact, provides an efficient port for neuroinvasion [80]. Neurotropic, but also non-neurotropic, viruses may use this gateway to enter the CNS using the BBB disruption caused by the activated inflammatory processes [80]. Moreover, the inflammatory response (in particular proinflammatory cytokines) can enhance BBB permeability promoting the transendothelial migration of T cells (activated against the virus), which can damage the OX hypothalamic neurons [81]. The documentation of olfactory dysfunction in patients with narcolepsy can reinforce this hypothesis and highlight the role of olfactory bulb in the pathogenic mechanisms of narcolepsy [82].

Taking these hypotheses into account, the main message of this review to sleep medicine clinicians and researches is to consider SARS-CoV2 infection as a possibly triggering event leading to narcolepsy. The previous experience of Influenza-A H1N1 infection and vaccination should raise the opportunity to monitor subjects affected with COVID-19 also after resolution of the infection since the occurrence of EDS (in same cases already present during the infection) may represent a preliminary manifestation of OX dysfunction.


Both retrospective analysis achieved by reviewing clinical charts of patients with COVID-19 and prospective observational studies [2, 83, 84] provided compelling evidence on the CNS involvement during SARS-CoV2 infection, which definitely supports the hypothesis of a neuropathogenic effect of the virus. Early experimental data on SARS-CoV2 and existing literature about other coronaviruses allow supposing several mechanisms of neuroinvasion of the virus, including the trans-synaptic spread from peripheral nerves, the BBB passage mediated by ACE2 receptors or abnormal permeability, and the “Trojan horse” strategy due to the brain entrance of immune cells infected through ACE2 receptors [2, 6].

This brief narrative review summarized the mechanisms of CNS affection during SARS-CoV2 infection, which include different pathways and pathogenic cascades, concluding in chronic neuroinflammatory or neurodegenerative processes that typically underlie both common (PD and MS) or rare (narcolepsy) neurological diseases. In addition to direct neuronal injury, we also highlighted how SARS-CoV2 might have a role in the successive development of these chronic neurological disorders because of the activation of systemic inflammatory response, favouring a culprit unbalance in the immune system or affecting other critical players of neurodegeneration and neuroinflammation, such as BBB integrity and gut–brain axis (Fig. 1).

Fig. 1

SARS-CoV2-induced mechanisms for neuropathogenicity. The scheme represents direct and indirect effects of COVID-19 that overlap with defined pathogenic mechanisms of common and rare chronic neurological disorders, suggesting its potential role as risk factor

Although long-term neuropathogenic effect of SARS-CoV2 has not yet been proven in experimental settings, available knowledge on both COVID-19 clinical events and established pathophysiological dynamics of chronic neurological disorders lead us to look at SARS-CoV2 infection as a potential trigger or risk factor for neurological disorders.

In conclusion, prospective neurological follow-up of both COVID-19 survivors and asymptomatic infected individuals, and case–control observational studies are mandatory to establish the effective long-term neuropathogenicity of the virus and achieve early diagnosis and timely therapeutic interventions. On the other hand, COVID-19 should be considered a critical anamnestic cue and serology for SARS-CoV2 infection can be planned when approaching patients with neuroinflammatory, neurodegenerative, or sleep disorders.


  1. 1.

    Ellul M, Benjamin L, Singh B et al (2020) Neurological associations of COVID-19. SSRN Electron J.

    Article  Google Scholar 

  2. 2.

    Zubair AS, McAlpine LS, Gardin T et al (2020) Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review. JAMA Neurol.

    Article  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Schirinzi T, Cerroni R, Di Lazzaro G et al (2020) Self-reported needs of patients with Parkinson’s disease during COVID-19 emergency in Italy. Neurol Sci.

    Article  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Schirinzi T, Di Lazzaro G, Salimei C et al (2020) Physical activity changes and correlate effects in patients with Parkinson’s disease during COVID-19 lockdown. Mov Disord Clin Pract.

    Article  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Lippi A, Domingues R, Setz C et al (2020) SARS-CoV-2: at the crossroad between aging and neurodegeneration. Mov Disord.

    Article  PubMed  PubMed Central  Google Scholar 

  6. 6.

    Natoli S, Oliveira V, Calabresi P et al (2020) Does SARS-Cov-2 invade the brain? Translational lessons from animal models. Eur J Neurol.

    Article  PubMed  PubMed Central  Google Scholar 

  7. 7.

    Kalia LV, Lang AE (2015) Parkinson’s disease. Lancet 386:896–912.

    CAS  Article  Google Scholar 

  8. 8.

    Petrillo S, Schirinzi T, Di Lazzaro G et al (2019) Systemic activation of Nrf2 pathway in Parkinson’s disease. Mov Disord.

    Article  PubMed  Google Scholar 

  9. 9.

    Imbriani P, D’Angelo V, Platania P et al (2020) Ischemic injury precipitates neuronal vulnerability in Parkinson’s disease: insights from PINK1 mouse model study and clinical retrospective data. Park Relat Disord 74:57–63.

    Article  Google Scholar 

  10. 10.

    Meng L, Shen L, Ji HF (2019) Impact of infection on risk of Parkinson’s disease: a quantitative assessment of case-control and cohort studies. J Neurovirol 25:221–228.

    Article  PubMed  Google Scholar 

  11. 11.

    Marreiros R, Müller-Schiffmann A, Trossbach SV et al (2020) Disruption of cellular proteostasis by H1N1 influenza A virus causes α-synuclein aggregation. Proc Natl Acad Sci USA 117:6741–6751.

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Wang R, Zhu Y, Lin X et al (2019) Influenza M2 protein regulates MAVS-mediated signaling pathway through interacting with MAVS and increasing ROS production. Autophagy 15:1163–1181.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  13. 13.

    To EE, Erlich JR, Liong F et al (2020) Mitochondrial reactive oxygen species contribute to pathological inflammation during influenza A virus infection in mice. Antioxid Redox Signal 32:929–942.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  14. 14.

    Schirinzi T, Martella G, Imbriani P et al (2019) Dietary Vitamin E as a protective factor for Parkinson’s Disease: clinical and experimental evidence. Front Neurol 10:148.

    Article  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Pisani V, Stefani A, Pierantozzi M et al (2012) Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson’s disease. J Neuroinflammation 9:670.

    CAS  Article  Google Scholar 

  16. 16.

    Schirinzi T, Di Lazzaro G, Sancesario GM et al (2020) Young-onset and late-onset Parkinson’s disease exhibit a different profile of fluid biomarkers and clinical features. Neurobiol Aging.

    Article  PubMed  Google Scholar 

  17. 17.

    Schirinzi T, Madeo G, Martella G et al (2016) Early synaptic dysfunction in Parkinson’s disease: insights from animal models. Mov Disord 31:802–813.

    Article  PubMed  Google Scholar 

  18. 18.

    Lechien JR, Chiesa-Estomba CM, De Siati DR et al (2020) Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol.

    Article  PubMed  PubMed Central  Google Scholar 

  19. 19.

    Rey NL, Wesson DW, Brundin P (2018) The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases. Neurobiol Dis 109:226–248.

    CAS  Article  PubMed  Google Scholar 

  20. 20.

    Schirinzi T, Sancesario GM, Di Lazzaro G et al (2018) CSF α-synuclein inversely correlates with non-motor symptoms in a cohort of PD patients. Parkinsonism Relat Disord.

    Article  PubMed  Google Scholar 

  21. 21.

    Rey NL, George S, Steiner JA et al (2018) Spread of aggregates after olfactory bulb injection of α-synuclein fibrils is associated with early neuronal loss and is reduced long term. Acta Neuropathol 135:65–83.

    CAS  Article  PubMed  Google Scholar 

  22. 22.

    Krashia P, Cordella A, Nobili A et al (2019) Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson’s disease. Nat Commun 10:3945.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  23. 23.

    Ye Q, Wang B, Mao J (2020) Cytokine storm in COVID-19 and treatment. J Infect.

    Article  PubMed  PubMed Central  Google Scholar 

  24. 24.

    Henry BM, de Oliveira MHS, Benoit S et al (2020) Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med.

    Article  PubMed  Google Scholar 

  25. 25.

    Qin XY, Zhang SP, Cao C et al (2016) Aberrations in peripheral inflammatory cytokine levels in Parkinson disease: a systematic review and meta-analysis. JAMA Neurol 73:1316–1324.

    Article  PubMed  Google Scholar 

  26. 26.

    Qiu X, Xiao Y, Wu J et al (2019) C-reactive protein and risk of Parkinson’s Disease: a systematic review and meta-analysis. Front Neurol 10:384.

    Article  PubMed  PubMed Central  Google Scholar 

  27. 27.

    Maass F, Schulz I, Lingor P et al (2019) Cerebrospinal fluid biomarker for Parkinson’s disease: an overview. Mol Cell Neurosci 97:60–66

    CAS  Article  Google Scholar 

  28. 28.

    Cervellati C, Trentini A, Pecorelli A, Valacchi G (2020) Inflammation in neurological disorders: the thin boundary between brain and periphery. Antioxid Redox Signal.

    Article  PubMed  Google Scholar 

  29. 29.

    Mao R, Qiu Y, He JS et al (2020) Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol.

    Article  PubMed  PubMed Central  Google Scholar 

  30. 30.

    Zhou J, Li C, Liu X et al (2020) Infection of bat and human intestinal organoids by SARS-CoV-2. Nat Med.

    Article  PubMed  PubMed Central  Google Scholar 

  31. 31.

    Matheoud D, Cannon T, Voisin A et al (2019) Intestinal infection triggers Parkinson’s disease-like symptoms in Pink1 −/− mice. Nature 571:565–569.

    CAS  Article  PubMed  Google Scholar 

  32. 32.

    Dhar D, Mohanty A (2020) Gut microbiota and Covid-19- possible link and implications. Virus Res 285:198018.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  33. 33.

    Borghammer P (2018) How does Parkinson’s disease begin? Perspectives on neuroanatomical pathways, prions, and histology. Mov Disord 33:48–57.

    Article  PubMed  Google Scholar 

  34. 34.

    Rogers JP, Chesney E, Oliver D et al (2020) Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry.

    Article  PubMed  PubMed Central  Google Scholar 

  35. 35.

    Alwardat M, Schirinzi T, Di Lazzaro G et al (2019) Association between physical activity and dementia’s risk factors in patients with Parkinson’s disease. J Neural Transm 126:319–325.

    Article  PubMed  Google Scholar 

  36. 36.

    Vlajinac H, Sipetic S, Marinkovic J et al (2013) The stressful life events and Parkinson’s disease: a case-control study. Stress Heal 29:50–55.

    Article  Google Scholar 

  37. 37.

    Filippi M, Brück W, Chard D et al (2019) Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol 18:198–210

    Article  Google Scholar 

  38. 38.

    van Langelaar J, Rijvers L, Smolders J, van Luijn MM (2020) B and T cells driving multiple sclerosis: identity mechanisms and potential triggers. Front Immunol 11:760.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  39. 39.

    Soldan SS, Jacobson S (2016) Virus-induced demyelination: The case for virus(es) in multiple sclerosis. In: Neurotropic Viral Infections, vol 2. Neurotropic Retroviruses, DNA Viruses, Immunity and Transmission. Springer International Publishing, pp 175–220

  40. 40.

    Bar-Or A, Pender MP, Khanna R et al (2020) Epstein-Barr virus in multiple sclerosis: theory and emerging immunotherapies. Trends Mol Med 26:296–310

    CAS  Article  Google Scholar 

  41. 41.

    Guan Y, Jakimovski D, Ramanathan M et al (2019) The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to in vivo imaging. Neural Regen Res 14:373–386

    Article  Google Scholar 

  42. 42.

    Handel AE, Williamson AJ, Disanto G et al (2010) An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. PLoS ONE 5:e12496.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  43. 43.

    Kumar N, Sharma S, Barua S, Tripathi BN, Rouse BT (2018) Virological and immunological outcomes of coinfections. Clin Microbiol Rev 31(4):e00111–e00117.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  44. 44.

    Desforges M, Le Coupanec A, Dubeau P, et al (2019) Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? Viruses 12(1):14.

    Article  Google Scholar 

  45. 45.

    Salmi A, Ziola B, Hovi T, Reunanen M (1982) Antibodies to coronaviruses OC43 and 229E in multiple sclerosis patients. Neurology 32:292–295.

    CAS  Article  PubMed  Google Scholar 

  46. 46.

    Libbey JE, Fujinami RS (2010) Potential triggers of MS. Results Probl Cell Differ 51:21–42.

    CAS  Article  PubMed  Google Scholar 

  47. 47.

    Louapre C, Collongues N, Stankoff B et al (2020) Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol.

    Article  PubMed  Google Scholar 

  48. 48.

    Sormani MP (2020) Italian Study Group on COVID-19 infection in multiple sclerosis. An Italian programme for COVID-19 infection in multiple sclerosis. Lancet Neurol 19(6):481–482.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  49. 49.

    Boucher A, Desforges M, Duquette P, Talbot PJ (2007) Long-term human coronavirus-myelin cross-reactive T-cell clones derived from multiple sclerosis patients. Clin Immunol 123:258–267.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  50. 50.

    Liu J, Li S, Liu J et al (2020) Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine 55:102763.

    Article  PubMed  PubMed Central  Google Scholar 

  51. 51.

    Xie J, Fan HW, Li TS et al (2006) Dynamic changes of T lymphocyte subsets in the long-term follow-up of severe acute respiratory syndrome patients. Acta Acad Med Sin 28:253–255

    Google Scholar 

  52. 52.

    Cossarizza A, De Biasi S, Guaraldi G et al (2020) SARS-CoV-2, the virus that causes COVID-19: cytometry and the new challenge for global health. Cytom Part A 97:340–343.

    CAS  Article  Google Scholar 

  53. 53.

    Scheidl E, Canseco DD, Hadji-Naumov A, Bereznai B (2020) Guillain-Barre syndrome during SARS-CoV-2 pandemic: a case report and review of recent literature. J Peripher Nerv Syst.

    Article  PubMed  PubMed Central  Google Scholar 

  54. 54.

    Chen T, Song J, Liu H et al. (2020) Positive Epstein-Barr virus detection in corona virus disease 2019 (COVID-19) patients.

  55. 55.

    Rinaldi F, Federle L, Puthenparampil M et al (2018) Evidence of B-cell dysregulation in severe CNS inflammation after alemtuzumab therapy. Neurol Neuroimmunol NeuroInflammation.

    Article  Google Scholar 

  56. 56.

    Kunkl M, Frascolla S, Amormino C et al (2020) T Helper cells: the modulators of inflammation in multiple sclerosis. Cells 9:482.

    CAS  Article  PubMed Central  Google Scholar 

  57. 57.

    Buscarinu MC, Fornasiero A, Romano S et al (2019) The contribution of gut barrier changes to multiple sclerosis pathophysiology. Front Immunol 10:1916.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  58. 58.

    Zanin L, Saraceno G, Panciani PP et al (2020) SARS-CoV-2 can induce brain and spine demyelinating lesions. Acta Neurochir (Wien).

    Article  Google Scholar 

  59. 59.

    Murray RS, Brown B, Brain D, Cabirac GF (1992) Detection of coronavirus RNA and antigen in multiple sclerosis brain. Ann Neurol 31:525–533.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  60. 60.

    Stewart JN, Mounir S, Talbot PJ (1992) Human coronavirus gene expression in the brains of multiple sclerosis patients. Virology 191:502–505.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  61. 61.

    Dessau RB, Lisby G, Frederiksen JL (2001) Coronaviruses in brain tissue from patients with multiple sclerosis. Acta Neuropathol 101:601–604.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  62. 62.

    Arbour N, Day R, Newcombe J, Talbot PJ (2000) Neuroinvasion by human respiratory coronaviruses. J Virol 74:8913–8921.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  63. 63.

    Acquavella J, Mehra R, Bron M et al (2020) Prevalence of narcolepsy, other sleep disorders, and diagnostic tests from 2013–2016: insured patients actively seeking care. J Clin Sleep Med.

    Article  PubMed  Google Scholar 

  64. 64.

    Sarkanen TO, Alakuijala APE, Dauvilliers YA, Partinen MM (2018) Incidence of narcolepsy after H1N1 influenza and vaccinations: systematic review and meta-analysis. Sleep Med Rev 38:177–186

    Article  Google Scholar 

  65. 65.

    AASM (2014) American Academy of Sleep Medicine. International Classification of Sleep Disorders, 3rd edn (AASM)

  66. 66.

    Nishino S, Ripley B, Overeem S et al (2000) Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355:39–40.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  67. 67.

    Thannickal TC (2009) A decade of hypocretin/orexin: accomplishments in sleep medicine. Sleep Med Rev 13:5–8

    Article  Google Scholar 

  68. 68.

    Bassetti CLA, Adamantidis A, Burdakov D et al (2019) Narcolepsy—clinical spectrum, aetiopathophysiology, diagnosis and treatment. Nat Rev Neurol 15:519–539

    Article  Google Scholar 

  69. 69.

    Kornum BR, Pizza F, Knudsen S et al (2015) Cerebrospinal fluid cytokine levels in type 1 narcolepsy patients very close to onset. Brain Behav Immun 49:54–58.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  70. 70.

    Dauvilliers Y, Jaussent I, Lecendreux M et al (2014) Cerebrospinal fluid and serum cytokine profiles in narcolepsy with cataplexy: a case-control study. Brain Behav Immun 37:260–266.

    CAS  Article  PubMed  Google Scholar 

  71. 71.

    van der Heide A, Hegeman-Kleinn IM, Peeters E et al (2015) Immunohistochemical screening for antibodies in recent onset type 1 narcolepsy and after H1N1 vaccination. J Neuroimmunol 283:58–62.

    CAS  Article  PubMed  Google Scholar 

  72. 72.

    Pedersen NW, Holm A, Kristensen NP et al (2019) CD8 + T cells from patients with narcolepsy and healthy controls recognize hypocretin neuron-specific antigens. Nat Commun.

    Article  PubMed  PubMed Central  Google Scholar 

  73. 73.

    Mohammadi S, Mayeli M, Saghazadeh A, Rezaei N (2020) Cytokines in narcolepsy: a systematic review and meta-analysis. Cytokine 131:155103.

    CAS  Article  PubMed  Google Scholar 

  74. 74.

    Kallweit U, Hidalgo H, Engel A et al (2012) Post H1N1 vaccination narcolepsy-cataplexy with decreased CSF beta-amyloid. Sleep Med 13:323

    Article  Google Scholar 

  75. 75.

    Liguori C, Placidi F, Albanese M et al (2014) CSF beta-amyloid levels are altered in narcolepsy: a link with the inflammatory hypothesis? J Sleep Res 23:420–424.

    Article  PubMed  Google Scholar 

  76. 76.

    Liguori C, Placidi F, Izzi F et al (2016) Beta-amyloid and phosphorylated tau metabolism changes in narcolepsy over time. Sleep Breath 20:277–283.

    Article  PubMed  Google Scholar 

  77. 77.

    Moresco M, Lecciso M, Ocadlikova D et al (2018) Flow cytometry analysis of T-cell subsets in cerebrospinal fluid of narcolepsy type 1 patients with long-lasting disease. Sleep Med 44:53–60.

    Article  PubMed  Google Scholar 

  78. 78.

    Wu Y, Xu X, Chen Z, et al (2020) Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun 87:18–22.

    CAS  Article  Google Scholar 

  79. 79.

    Mori I (2019) The olfactory bulb: a link between environmental agents and narcolepsy. Med Hypotheses 126:66–68.

    Article  PubMed  Google Scholar 

  80. 80.

    Mori I (2015) Transolfactory neuroinvasion by viruses threatens the human brain. Acta Virol 59:338–349

    CAS  Article  Google Scholar 

  81. 81.

    Li Y, Fu L, Gonzales DM, Lavi E (2004) Coronavirus neurovirulence correlates with the ability of the virus to induce proinflammatory cytokine signals from astrocytes and microglia. J Virol 78:3398–3406.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  82. 82.

    Bayard S, Plazzi G, Poli F et al (2010) Olfactory dysfunction in narcolepsy with cataplexy. Sleep Med 11:876–881.

    Article  PubMed  Google Scholar 

  83. 83.

    Liguori C, Pierantozzi M, Spanetta M et al (2020) Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection. Brain Behav Immun.

    Article  PubMed  PubMed Central  Google Scholar 

  84. 84.

    Mao L, Jin H, Wang M et al (2020) Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol.

    Article  PubMed  PubMed Central  Google Scholar 

Download references


Open access funding provided by Università degli Studi di Roma Tor Vergata within the CRUI-CARE Agreement. The authors would thank Prof. Nicola Biagio Mercuri, Prof. Mariangela Pierantozzi, Prof. Antonio Pisani, Prof. Fabio Placidi, Prof. Alessandro Stefani, Dr. Girolama Alessandra Marfia from University of Roma Tor Vergata for the critical revision of the manuscript and the support in preparing it.


This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors

Author information



Corresponding authors

Correspondence to Tommaso Schirinzi, Doriana Landi or Claudio Liguori.

Ethics declarations

Conflicts of interest


Ethics approval

This study was conducted according with ethical principles of Helsinki declaration.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Schirinzi, T., Landi, D. & Liguori, C. COVID-19: dealing with a potential risk factor for chronic neurological disorders. J Neurol 268, 1171–1178 (2021).

Download citation


  • Parkinson’s disease
  • Multiple sclerosis
  • Narcolepsy
  • SARS-CoV2
  • COVID-19
  • Neuroinflammation
  • Risk factors
  • Neurodegeneration
  • Demyelination
  • Sleepiness